Johnson & Johnson had a good third quarter; revenue and earnings exceeded expectations, and the company also raised its outlook for this year. Both the pharmaceutical side and medical devices grew strongly, and earnings also clearly improved from last year.
The company plans to spin off its orthopedics business into its own DePuy Synthes company.
According to the CEO, the focus is now on six growth areas, such as cancer and cardiovascular disease treatment, and eye surgery.
https://x.com/Earnings_Time/status/1978045505977327996
